Author： Krauel Kerstin Simon Andrea Krause-Hebecker Nadine Czimbalmos Agnes Bottomley Andrew Flechtner Henning
Publisher： Informa Healthcare
ISSN： 1473-7167
Source： Expert Review of Pharmacoeconomics and Outcomes Research, Vol.12, Iss.6, 2012-12, pp. : 795-808
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
Health care `warranties' could pay for patients and providers
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 581, 2009-01 ,pp. :
Access to resources
Recommend
Health Canada has reminded hospitals that Anzemet [dolasetron] is contraindicated in patients aged
Reactions Weekly, Vol. 1, Iss. 1109, 2006-01 ,pp. :
Lenalidomide has demonstrated antitumour activity in patients with metastatic renal cancer
Inpharma, Vol. 1, Iss. 1574, 2007-01 ,pp. :
PD 115934 has limited antitumour activity in patients with recurrent endometrial cancer
Inpharma, Vol. 1, Iss. 1329, 2002-01 ,pp. :